Stock Price Quote

AUROMED LTD.

NSE : NABSE : 532103ISIN CODE : Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1995
Management Info
D Srinivasvaradan - Chairman D Srinivasvaradan - Managing Director
Registered Office

Address Srinilayam 1, Kannaiah Street, T Nagar,
Chennai,
Tamil Nadu-600017

Phone

Email --

Website NA

Registrars Details
Auromed Ltd.
Srinilayam 1, Kannaiah Street, T Nagar,Chennai
Listing : BSE

NEWS

No News Found

Financials

in Millions
QTR ANNUAL
Net Profit
Gross Profit
Operating Profit
Net Sales

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Ajanta Pharma (BSE)
peergroup  2558.40 (2.61%)
M.Cap ( in Cr)31957.51
Coral Laboratories (BSE)
peergroup  807.60 (8.54%)
M.Cap ( in Cr)288.52
Vimta Labs (BSE)
peergroup  1119.70 (3.91%)
M.Cap ( in Cr)2488.29
Mercury Laboratories (BSE)
peergroup  849.00 (3.78%)
M.Cap ( in Cr)101.88
Aarti Drugs (BSE)
peergroup  410.85 (7.20%)
M.Cap ( in Cr)3749.83

Shareholding Pattern

No Data Found

About Auromed Ltd.

Auromed Ltd. was incorporated in the year 1995. Its today's share price is 0. Its current market capitalisation stands at Rs 0 Cr. In the latest quarter, company has reported Gross Sales of Rs. 14.95 Cr and Total Income of Rs.15.94 Cr. The company's management includes V Haranath Reddy, BM Vasishta, S Nappinai, D Srinivasvaradan, D Srinivasvaradan, P Mukunda Reddy.

It is listed on the BSE with a BSE Code of 532103 , NSE with an NSE Symbol of and ISIN of . It's Registered office is at Srinilayam 1, Kannaiah Street, T NagarChennai-600017, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.